2024-517107-37-00已完成1 期
Study to compare drug availability in bloodstream of two oral formulations of mesalazine in healthy volunteers under fed conditions.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
FAES FARMA Clinical department
Scientific
Faes Farma S.A.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparative Bioavailability of Smartech 2% Sodium Diclofenac Topical Solution and PENNSAID 2% Applied to the Knees of Healthy Male and Female SubjectsOsteoarthritisACTRN12622001391763Avance Clinical Pty Ltd32
进行中（未招募）
不适用
Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart following Subcutaneous Insulin Infusion (CSII) - Basal Rate Resolution.Type 1 diabetes mellitusContinious subcutaneous insulin infusion (CSII)MedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2007-001912-21-DKAarhus Sygehus, Universityhospital of Aarhus
进行中（未招募）
不适用
Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart administered in the Duodenum in healthy volunteers – an open single blinded and uncontrolled exploratory trialDiabetes MellitusEUCTR2006-002803-15-DKAarhus Sygehus12
进行中（未招募）
1 期
Relative bioavailability and comparative pharmacokinetics (blood levels of the drug) of 13-CRA oral liquid and capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in children requiring treatment cycles of 13-CRA.euroblastomaMedDRA version: 20.0 Level: PT Classification code 10029260 Term: Neuroblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10029212 Term: Nervous system neoplasms malignant NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: HLGT Classification code 10029211 Term: Nervous system neoplasms malignant and unspecified NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005104-25-GBova BioPharma Limited20
尚未招募
1 期
Comparative evaluation of the absorption and disposition in the body of a generic formulation of darifenacin 15 mg against the innovator product in healthy fed volunteers.Bioequivalence assessment between two formulations of darifenacin 15 mg.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12610000894099Center for Clinical Pharmacology Research Bdbeq S.A.24